GLAXF News and Press, GlaxoSmithKline Plc From 05/14/20

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/11/2020. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

Orchard Therapeutics ( ORTX ) is an undercovered, $1.7bn London-headquartered company positioning itself to be the market leader in next-generation, cryopreserved, easily accessible, lentiviral vector based gene therapy. The company originally had 2 gene therapy assets. In 2018, Orchard Therap...

Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...

Background This is Part 2 of a 2-part set of articles about Gilead ( GILD ); Part 1 focused on its remdesivir ("RDV") for COVID-19. There is probably more going on at GILD than the focus on RDV in GILD's recent Q1 earnings report and conference call could allow to be discussed. The ...

Musings Unless you are solely invested in Technology stocks, your portfolio is likely nothing but a sea of red this year (despite a bump off the lows in April). Basically everything is hurting (no shocker there), but that’s not what I’m focused on at the moment. I’m tryi...

GlaxoSmithKline plc (GSK) Q1 2020 Results Conference Call April 29, 2020 09:00 AM ET Company Participants Sarah Elton-Farr - Head, IR Emma Walmsley - CEO Luke Miels - President, Global Pharmaceuticals Iain Mackay - CFO Hal Barron - Chief Scientific Officer and President, R&am...

The following slide deck was published by GlaxoSmithKline plc in conjunction with their 2020 Q1 earnings Read more ...

Tonix Goes Ahead with Late Stage Fibromyalgia Tonix Pharmaceuticals Holding Corp. ( TNXP ) announced that it has hit 50 percent enrollment milestone for its Phase 3 RELIEF trial. The trial will incorporate a pivotal study of TNX-102 SL 5.6 mg for managing fibromyalgia. The drug candidate ...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

Musings Shorter update this month since life is too crazy to look backwards at the moment, plus I made a ton of trades to report (so no gory graphs demonstrating the pain I am sure that your portfolio dashboard is telling you). I don’t believe that any of the posted numbers (espec...